These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 30891423)
21. Elevated PD-L1 expression predicts poor survival outcomes in patients with cervical cancer. Gu X; Dong M; Liu Z; Mi Y; Yang J; Zhang Z; Liu K; Jiang L; Zhang Y; Dong S; Shi Y Cancer Cell Int; 2019; 19():146. PubMed ID: 31143091 [TBL] [Abstract][Full Text] [Related]
22. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677 [No Abstract] [Full Text] [Related]
23. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Huang ZL; Liu S; Wang GN; Zheng SH; Ding SR; Tao YL; Chen C; Liu SR; Yang X; Chang H; Wang XH; Xia YF Cancer Cell Int; 2019; 19():141. PubMed ID: 31139018 [TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Liu X; Shan C; Song Y; Du J Front Oncol; 2019; 9():1111. PubMed ID: 31709181 [No Abstract] [Full Text] [Related]
25. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis. Yang L; Xue R; Pan C Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869 [No Abstract] [Full Text] [Related]
26. Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients. Gu X; Gao XS; Xiong W; Guo W; Han L; Bai Y; Peng C; Cui M; Xie M Onco Targets Ther; 2016; 9():4805-13. PubMed ID: 27536144 [TBL] [Abstract][Full Text] [Related]
27. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599 [TBL] [Abstract][Full Text] [Related]
28. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma. Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947 [TBL] [Abstract][Full Text] [Related]
29. Prognostic and Clinicopathological Value of PD-L1 in Melanoma: A Meta-Analysis. Xu J; Wang F; Yan Y; Zhang Y; Du Y; Sun G Am J Med Sci; 2020 Jun; 359(6):339-346. PubMed ID: 32498941 [TBL] [Abstract][Full Text] [Related]
30. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. Li J; Wang P; Xu Y PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812 [TBL] [Abstract][Full Text] [Related]
31. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L Front Pharmacol; 2019; 10():139. PubMed ID: 30873025 [No Abstract] [Full Text] [Related]
32. The prognostic value of programmed cell death ligand 1 expression in non-Hodgkin lymphoma: a meta-analysis. Zhao S; Zhang M; Zhang Y; Meng H; Wang Y; Liu Y; Jing J; Huang L; Sun M; Zhang Y; Zhang Q Cancer Biol Med; 2018 Aug; 15(3):290-298. PubMed ID: 30197796 [TBL] [Abstract][Full Text] [Related]
33. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153 [TBL] [Abstract][Full Text] [Related]
34. The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures. Shi T; Zhu S; Guo H; Li X; Zhao S; Wang Y; Lei X; Huang D; Peng L; Li Z; Xu S Front Oncol; 2021; 11():567978. PubMed ID: 33708622 [TBL] [Abstract][Full Text] [Related]
35. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K Front Oncol; 2019; 9():883. PubMed ID: 31572677 [TBL] [Abstract][Full Text] [Related]
36. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984 [TBL] [Abstract][Full Text] [Related]
37. Prognostic value of long non-coding RNA FOXD2-AS1 expression in patients with solid tumors. Zhou L; Li Z; Shao X; Yang B; Feng J; Xu L; Teng Y Pathol Res Pract; 2019 Sep; 215(9):152449. PubMed ID: 31378453 [TBL] [Abstract][Full Text] [Related]
38. An Up-To-Date Investigation Into the Correlation Between Proton Pump Inhibitor Use and the Clinical Efficacy of Immune Checkpoint Inhibitors in Advanced Solid Cancers: A Systematic Review and Meta-Analysis. Liu C; Guo H; Mao H; Tong J; Yang M; Yan X Front Oncol; 2022; 12():753234. PubMed ID: 35280736 [TBL] [Abstract][Full Text] [Related]
39. Prognostic value of programmed cell death ligand-1 expression in the tumor-infiltrating immune cells of patients with lung cancer: A meta-analysis. Berele BA; Yang G; Wu T Mol Clin Oncol; 2021 Aug; 15(2):167. PubMed ID: 34194745 [TBL] [Abstract][Full Text] [Related]
40. The predictive implication of programmed cell death ligand 1 expression in extranodal natural killer/T-Cell lymphoma and its correlation with clinicopathological features: a systematic review and meta-analysis. Li W; Zheng Q; Luo X; Zhang X; Zheng X; Yang Y Transl Cancer Res; 2023 Aug; 12(8):2115-2127. PubMed ID: 37701117 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]